{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T17:13:01Z","timestamp":1780679581229,"version":"3.54.1"},"reference-count":23,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,1,5]],"date-time":"2017-01-05T00:00:00Z","timestamp":1483574400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01CA044991"],"award-info":[{"award-number":["P01CA044991"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32CA009515\u201030"],"award-info":[{"award-number":["5T32CA009515\u201030"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24CA184039"],"award-info":[{"award-number":["K24CA184039"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21CA119519"],"award-info":[{"award-number":["R21CA119519"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fenretinide, a synthetic retinoid, induces apoptotic cell death in B\u2010cell non\u2010Hodgkin lymphoma (B\u2010<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>) and acts synergistically with rituximab in preclinical models. We report results from a phase I\u2010II study of fenretinide with rituximab for B\u2010<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>s. Eligible diagnoses included indolent B\u2010<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content> or mantle cell lymphoma. The phase I design de\u2010escalated from fenretinide at 900\u00a0mg\/m<jats:sup>2<\/jats:sup> <jats:styled-content style=\"fixed-case\">PO BID<\/jats:styled-content> for days 1\u20135 of a 7\u2010day cycle. The phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> portion added 375\u00a0mg\/m<jats:sup>2<\/jats:sup> <jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content> rituximab weekly on weeks 5\u20139 then every 3\u00a0months. Fenretinide was continued until progression or intolerance. Thirty\u2010two patients were treated: 7 in phase I, and 25 in phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> of the trial. No dose\u2010limiting toxicities were observed. The phase II component utilized fenretinide 900\u00a0mg\/m<jats:sup>2<\/jats:sup> twice daily with rituximab. The most common treatment\u2010related adverse events of grade 3 or higher were rash (<jats:italic>n<\/jats:italic>\u00a0=\u00a03) and neutropenia (<jats:italic>n<\/jats:italic>\u00a0=\u00a03). Responses were seen in 6 (24%) patients on the phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> study, with a median duration of response of 47\u00a0months (95% confidence interval, 2\u201356). The combination of fenretinide and rituximab was well tolerated, yielded a modest overall response rate, but with prolonged remission durations. Further study should focus on identifying the responsive subset of B\u2010<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.14451","type":"journal-article","created":{"date-parts":[[2017,1,5]],"date-time":"2017-01-05T16:12:44Z","timestamp":1483632764000},"page":"583-590","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Results of a phase I\u2010II study of fenretinide and rituximab for patients with indolent B\u2010cell lymphoma and mantle cell lymphoma"],"prefix":"10.1111","volume":"176","author":[{"given":"Andrew J.","family":"Cowan","sequence":"first","affiliation":[{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center Seattle WA USA"},{"name":"Division of Medical Oncology, Department of Medicine University of Washington Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip A.","family":"Stevenson","sequence":"additional","affiliation":[{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted A.","family":"Gooley","sequence":"additional","affiliation":[{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shani L.","family":"Frayo","sequence":"additional","affiliation":[{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George R.","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Department of Radiology Harvard Medical School, MGH Hospital Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Smith","sequence":"additional","affiliation":[{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center Seattle WA USA"},{"name":"Division of Medical Oncology, Department of Medicine University of Washington Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian J.","family":"Green","sequence":"additional","affiliation":[{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center Seattle WA USA"},{"name":"Division of Medical Oncology, Department of Medicine University of Washington Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Roden","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine University of Washington Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Pagel","sequence":"additional","affiliation":[{"name":"Swedish Cancer Institute Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent L.","family":"Wood","sequence":"additional","affiliation":[{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center Seattle WA USA"},{"name":"Division of Hematopathology Department of Laboratory Medicine, University of Washington Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver W.","family":"Press","sequence":"additional","affiliation":[{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center Seattle WA USA"},{"name":"Division of Medical Oncology, Department of Medicine University of Washington Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center Seattle WA USA"},{"name":"Division of Medical Oncology, Department of Medicine University of Washington Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,1,5]]},"reference":[{"key":"e_1_2_9_2_1","first-page":"14","article-title":"Pharmacokinetics of all\u2010trans\u2010retinoic acid: clinical implications in acute promyelocytic leukemia","volume":"31","author":"Adamson P.C.","year":"1994","journal-title":"Seminars in Hematology"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.5.1238"},{"key":"e_1_2_9_4_1","first-page":"4179","article-title":"Different ways to induce apoptosis by fenretinide and all\u2010trans\u2010retinoic acid in human B lymphoma cells","volume":"25","author":"Barna G.","year":"2005","journal-title":"Anticancer Research"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.3816\/CGC.2009.n.008"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/18.5.943"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(02)00162-5"},{"key":"e_1_2_9_10_1","first-page":"6149","article-title":"Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow\u2010up study of breast cancer patients","volume":"49","author":"Formelli F.","year":"1989","journal-title":"Cancer Research"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2795"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/11201110-000000000-00000"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1006\/excr.2000.4988"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24643"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1228-x"},{"key":"e_1_2_9_16_1","first-page":"2138","article-title":"Clinical pharmacology of oral all\u2010trans retinoic acid in patients with acute promyelocytic leukemia","volume":"52","author":"Muindi J.R.","year":"1992","journal-title":"Cancer Research"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19990531)81:5<829::AID-IJC26>3.0.CO;2-3"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2014.10.004"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.09.096"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2013.00006"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-009-9228-6"},{"key":"e_1_2_9_22_1","first-page":"2490","article-title":"Synergistic effects of the fenretinide (4\u2010HPR) and anti\u2010CD20 monoclonal antibodies on apoptosis induction of malignant human B cells","volume":"7","author":"Shan D.","year":"2001","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-005-5864-7"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-08-0100"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14451","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14451","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T03:14:21Z","timestamp":1696302861000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,5]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1111\/bjh.14451"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14451","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,5]]},"assertion":[{"value":"2016-08-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-09-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-01-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}